Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy
Overview
This trial compares the pharmacokinetics of palonosetron administered subcutaneously and intravenously.
Full Title of Study: “Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous (SC) Versus Intravenous Palonosetron in Cancer Patients Treated With Platinum Based Chemotherapy”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: November 2010
Detailed Description
5-Hydroxitryptamine3 antagonists are one of the mainstays of antiemetic treatment and they are administered either intravenously or orally. Nevertheless sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. Our objective is to evaluate the bioavailability of subcutaneous palonosetron.Patients receiving platinum-based chemotherapy will be randomized to receive palonosetron 3 mg either subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine samples will be collected after each cycle. Pharmacokinetics of subcutaneous and IV palonosetron will be prospectively compared.
Interventions
- Drug: Palonosetron
- Palonosetron 3 mg administered SC or IV
Arms, Groups and Cohorts
- Active Comparator: Intravenous palonosetron
- Intravenous palonosetron: control arm (standard treatment)
- Experimental: subcutaneous palonosetron
- subcutaneous palonosetron
Clinical Trial Outcome Measures
Primary Measures
- To assess the pharmacokinetics of a single dose of palonosetron 3mg administered either subcutaneously or intravenously by assessment of area under the curve and Cmax in cancer patients treated with emetogenic chemotherapy.
- Time Frame: Palonosetron levels will be assessed at 10 , 15, 30, 45, 60 min. and 12 and 24 hours following treatment
Secondary Measures
- To compare the efficacy of a single dose of palonosetron 3mg administered either subcutaneously or intravenously by assessment of number of episodes of nausea and vomiting in cancer patients treated with emetogenic chemotherapy.
- Time Frame: 1 week (post-chemotherapy)
Participating in This Clinical Trial
Inclusion Criteria
- Cancer patients receiving platinum-based chemotherapy adequate bone marrow, hepatic and renal function Exclusion Criteria:
- Pregnancy – Serious concomitant diseases, in the invesgator´s criteria
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Belen Sadaba, MD, PhD, Principal Investigator, Clinica Universidad de Navarra
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.